Using Alternative Data to Evaluate Pharmaceutical Pipelines
We summarise key findings of a research paper co-authored by a pharmaceutical data provider. Using Takeda Pharmaceutical’s FY 2017 Q4 pipeline as an example, we also evaluate how phase transition data can be used by investors to gain a better understanding of which drugs are most likely to be approved by the FDA and to analyse the health of a pharmaceutical company’s pipeline.